IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Other News
InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance
October 07, 2024 08:00 AM Eastern Daylight Time REDWOOD CITY, Calif.–(BUSINESS WIRE)–InterVene, Inc., a clinical-stage medical device company dedicated to developing interventional solutions for chronic venous insufficiency (CVI), announced today the closing of its $13M Series A financing round. The financing was co-led by new investor Treo Ventures and existing […]
Reprieve Cardiovascular Completes Enrollment in Randomized Pilot Trial Evaluating First-of-its-Kind Personalized Fluid Management System for Acute Decompensated Heart Failure
MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development-stage company pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced the completion of enrollment in the “Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (“FASTR”)” trial. “For decades, managing fluid removal in patients with […]
Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical
SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today filed a patent infringement lawsuit against Q’Apel Medical alleging infringement of five U.S. patents held by Route 92 Medical, which protect the Tenzing® delivery catheter. The complaint was filed October 7, 2024, in the United States District Court for the District of Delaware.
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August […]
Arineta Launches First SpotLight™ Duo in Northeast at Lehigh Valley Health Network
Caesarea, Israel – Oct. 3, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, announces the installation of its SpotLight™ Duo cardiac CT scanner at Lehigh Valley Health Network’s (LVHN) cardiac diagnostic center in Gilbertsville, Pennsylvania. This installation through Lehigh Valley Imaging makes the SpotLight Duo […]
Imperial College London Study Finds Eko Health AI Predicts Patients With High Risk of Major Adverse Cardiac Events
Patients identified with reduced ejection fraction using Eko Health AI were twice as likely to experience heart attacks, heart failure, hospitalization, and all-cause mortality over two years. SAN FRANCISCO, Oct. 2, 2024 /PRNewswire/ — Eko Health, a pioneer in applying artificial…
Boston Scientific Announces Conference Call Discussing Third Quarter 2024 Results
-Company to also host virtual webcast with a cardiology business update- MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September…
AMSEL MEDICAL SIGNS $7.45M PHASE III SBIR CONTRACT
Non-dilutive $7.45M Phase III SBIR Temporary Vascular Occlusion Clamp (TVOC) contract to commercialize innovative technology targeting hemorrhage control for the U.S. Air Force. CAMBRIDGE, Mass., Oct. 2, 2024 /PRNewswire/ — Amsel Medical Corporation today announces that it has been…
Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce™ XL Thrombectomy System. “Securing FDA clearance for the Pounce XL Thrombectomy System is a major step […]



